Brain Health

Find More: Dr. Gabrielle Lyon
- Advertisement -
Ad image

Brain Health Articles

Spring 2025 Comment on the USSC

The United States Sentencing Commission (USSC) had an opportunity during this most recent amendment cycle to make significant and meaningful

MAPS Announces MDMA-Assisted Therapy Education Event For Ukrainian Mental Health Practitioners

April 15, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit organization at the vanguard of the

Approval of clinical trial protocol

WCG IRB Canada certifies that the identified clinical trial complies with Good Clinical Practices as defined by the FDA, HHS,

Psychedelic Science 2025 Announces Select Speakers for the Leading Conference on Psychedelic Research, Policy, and Thought Leadership

March 7, 2025 — Psychedelic Science — the premier global gathering for psychedelic research, medicine, policy, and culture hosted by

MAPS Releases Template to Assist in Federal Drug Sentencing Reform Efforts

Washington D.C.; February 27, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit organization that has led

MAPS Announces Search for New Executive Director as it Doubles Down on Advocacy and Movement Building

FOR IMMEDIATE RELEASE: February 12, 2025 The Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit organization that has led

MAPS Submits Cannabis Data Safety Update Report 2024 and Protocol Amendment to FDA on Phase 2 Study of Smoked Cannabis for Veterans with PTSD (MJP2)

On January 15, 2025, MAPS submitted to the FDA the 2024 Cannabis Data Safety Update Report (DSUR) along with a protocol

The Ultimate Diet Coaching App: Why I Recommend Carbon

Navigating the world of nutrition and fitness apps can feel daunting. With countless options promising results, how do you decide

MAPS Successfully Clears Path for Cannabis Research through FDA Formal Dispute

FOR IMMEDIATE RELEASE: November 20, 2024 The U.S. Food and Drug Administration (FDA) Division of Psychiatry Products has cleared the